Molybdenum Cofactor Deficiency (MoCD) Type A
Molybdenum Cofactor Deficiency (MoCD) Type A
‹ Return to Disorder Directory

Molybdenum Cofactor Deficiency Type A header 2

Author: Geetanjali Rathore, MD
University of Nebraska Medical Center 

Children’s Hospital and Medical Center, Omaha, NE  

Reviewed: July 2021 


Molybdenum cofactor deficiency (MoCD) type A is a rare but devastating metabolic disease. It first appears in the newborn period. It is estimated to affect 1 in 200,000 newborns worldwide. 

MoCD typically appears in the first few weeks of life as: 

MoCD type A is rapidly progressive. It causes severe developmental delay and death within the first 4 years of life. A gene abnormality is responsible for MoCD. The changed gene causes a toxic sulfite to collect in the brain. The sulfite leads to brain dysfunction. An early diagnosis is critical to any chance of improving outcomes.  


Disorder Overview


There are three forms of MoCD. They are named types A, B, and C. MoCD type A is the most common form and the only one for which there is definitive therapy that improves outcome. 

The three forms have the same signs and symptoms. They are distinguished only by their genetic cause:  

  • MOCS1 gene mutations cause type A 
  • MOCS2 gene mutations cause type B 
  • GPHN gene mutations cause type C 

MoCD should be considered a possible diagnosis in infants with any of the following symptoms: 

  • Profound developmental delay 
  • Neonatal seizures 
  • Dysmorphic facial features 
  • Dislocated eye lenses 

The majority of children with MoCD die of the illness within the first few days or weeks of life. There are some reports of a milder form, with survival into adult life. There are also very rare reports of asymptomatic cases. 


Babies with this condition can appear normal at birth. However, within a week they develop seizures. The seizures do not improve with treatment. They are called intractable seizures.  

Over the course of illness, the infant can have: 

  • Frequent, intractable seizures 
  • Abnormal muscle tone (increased or decreased) 
  • Difficulty feeding  
  • Extreme fussiness 
  • Exaggerated startle 
  • Small head size (microcephaly) 
  • Facial features that may be coarse, with puffy cheeks/lips, a long face, and widely spaced eyes 
  • Dislocation of the eye lenses  

Affected babies usually do not survive past early childhood. 

Molybdenum Cofactor Deficiency Type A


MoCD is caused by mutations in one of three genes:  

  • MOCS1 
  • MOCS2 
  • GPHN  

The proteins produced by these genes help with processes that break down different toxins in the body. Without help from proteins made by these genes, these processes do not work. This leads to a buildup of certain toxins. One such toxin is the chemical sulfite.  

Damage to the brain caused by abnormally high levels of sulfite leads to: 

  • Encephalopathy  
  • Seizures  
  • Other symptoms of MoCD 

MoCD has an autosomal recessive pattern of inheritance. This means that a child must have both copies of the mutated gene to have MoCD. An affected baby usually inherits one abnormal copy of the gene from each parent. Parents of the affected child typically do not show signs and symptoms of the condition. They are usually asymptomatic carriers.  


Diagnosing MoCD 

When doctors suspect MoCD based what they observe in the baby, they use testing to learn more. Key biochemical markers can point to MoCD: 

  • Elevated sulfites (in urine test) 
  • Elevated S-sulfocysteine (in urine test) 
  • Low uric acid (in blood or urine test) 
  • High levels of xanthine and hypoxanthine (in blood test) 

Finally, genetic testing can confirm the diagnosis and type of MoCD.  

Other Investigations 

Magnetic Resonance Imaging (MRI)

MRI can create images of the brain. The images can reveal: 

  • Brain malformations 
  • Progressive, stroke-like changes 
  • Dislocated lenses of the eyes  
Share on social media:

Electroencephalogram (EEG)

An EEG can record electrical activity in the brain. This can help evaluate seizures and brain dysfunction.  

Share on social media:
Molybdenum Cofactor Deficiency Type A 2


New Medicine for MoCD Type A 

Until recently, the only treatment options for MoCD included supportive care and therapy for complications. The first drug treatment, fosdenopterin, was approved in 2021 for treating MoCD type A by the FDA.  

It is only effective at treating MoCD type A, not the other types. Lifelong therapy is recommended. Starting treatment as early as possible is recommended. This can reduce disease severity, as the brain injury is irreversible.  

Other Treatments 

Several other treatments are sometimes used for children with MoCD. 

Molybdate therapy

Molybdate may benefit those with mutations in the GEPH gene. 

Share on social media:

Pyridoxine (vitamin B6)

Pyridoxine has been shown to decrease seizure frequency. It does not affect the underlying metabolic defect. 

Share on social media:


MoCD type A is a rapidly progressive genetic disease. It cannot be outgrown. It has a high infant mortality rate. The median survival age is 3 years without treatment.  

Those who survive beyond the first few months without treatment often have severe developmental delays. This makes them highly dependent on others for assistance in tasks of daily living.  In addition, seizures are often frequent, daily, and disabling.  They can be very difficult to control.  Frequent hospitalizations are common. 

Early treatment with fosdenopterin has been shown to improve survival and reduce symptoms, including seizures. For this reason, it is critical to diagnose and treat MoCD type A as soon as possible.  

Ongoing interventions for MoCD type A will likely include: 

  • Daily injections of fosdenopterin  
  • Supportive measures, such as physical, occupational, and speech therapy 
  • Modifications in school, based on cognition and severity of disease 
Molybdenum Cofactor Deficiency Type A 3


Molybdenum Cofactor Deficiency Support Group 
The Molybdenum Cofactor Deficiency Support Group is a private support group on Facebook for families of children with all types of Molybdenum Cofactor Deficiency.

MoCD Type A: CNF Educational Video

Amy White, MS, CGC, is a genetic counselor Mayo Clinic Biochemical Genetics Laboratory and Whitney McHugh is the mother to a child living with MoCD Type A. In this video by the Child Neurology Foundation, they talk about MoCD Type A, getting a pediatric neurologic diagnosis and living with the rare disease.

Research for MoCD Type A are clinical trials that are recruiting or will be recruiting. Updates are made daily, so you are encouraged to check back frequently. is a database of privately and publicly funded clinical studies conducted around the world. This is a resource provided by the U.S. National Library of Medicine (NLM), which is an institute within the National Institutes of Health (NIH). Listing a study does not mean it has been evaluated by the U.S. Federal Government. Please read the NLM disclaimer for details.  

Before participating in a study, you are encouraged to talk to your health care provider and learn about the risks and potential benefits. 

The information in the CNF Child Neurology Disorder Directory is not intended to provide diagnosis, treatment, or medical advice and should not be considered a substitute for advice from a healthcare professional. Content provided is for informational purposes only.  CNF is not responsible for actions taken based on the information included on this webpage. Please consult with a physician or other healthcare professional regarding any medical or health related diagnosis or treatment options. 


Nagappa M, Bindu PS, Taly AB, Sinha S, Bharath RD. Child neurology: Molybdenum cofactor deficiency. Neurology. 2015 Dec 8;85(23):e175–8.   

Molybdenum cofactor deficiency, complementation group A; MOCODA. In: OMIM (Online Mendelian Inheritance in Man) [Genetic database].  

Share on social media:

Thank you to our 2023 Disorder Directory partners:

Start typing and press Enter to search

Shopping Cart